Trials / Terminated
TerminatedNCT05097131
An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
International Collaboration for Real-World Evidence in Alzheimer's Disease (ICARE AD)- A Prospective Real-World Observational Study of Aducanumab-avwa in Patients With Alzheimer's Disease in the US
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 29 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single-arm, multicenter, non-interventional study of aducanumab-avwa as prescribed in the post-marketing setting in the US. Investigators will be prescribing aducanumab-avwa and participants will be treated according to the standard of care (SoC). Participants will be followed up to 5 years after enrollment and data will be collected at routine visits every 6 to 12 months.
Conditions
Timeline
- Start date
- 2021-11-18
- Primary completion
- 2022-05-20
- Completion
- 2022-05-20
- First posted
- 2021-10-27
- Last updated
- 2023-04-18
Locations
22 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05097131. Inclusion in this directory is not an endorsement.